RESEARCH COMMUNICATION

Direct regulation of *nacre*, a zebrafish *MITF* homolog required for pigment cell formation, by the Wnt pathway

Richard I. Dorsky,^{1,3,4} David W. Raible,^{2,3} and Randall T. Moon^{1,3,5}

¹Howard Hughes Medical Institute and Department of Pharmacology, ²Department of Biological Structure, ³Center for Developmental Biology, University of Washington School of Medicine, Seattle, Washington 98195 USA

We have shown that Wnt signals are necessary and sufficient for neural crest cells to adopt pigment cell fates. *nacre*, a zebrafish homolog of *MITF*, is required for pigment cell differentiation. We isolated a promoter region of *nacre* that contains Tcf/Lef binding sites, which can mediate Wnt responsiveness. This promoter binds to zebrafish Lef1 protein in vitro, and a *nacre* reporter construct is strongly repressed by dominant-negative Tcf in melanoma cells. Mutation of Tcf/Lef sites abolishes Lef1 binding and reporter function in vivo. Wnt signaling therefore directly activates *nacre*, which in turn leads to pigment cell differentiation.

Received November 9, 1999; revised version accepted December 3, 1999.

Although the Wnt/ β -catenin signaling pathway functions throughout development (Cadigan and Nusse 1997), few target genes have been identified that mediate the roles of Wnt signaling in cell fate determination. Previous Wnt/ β -catenin target genes have been identified by promoter analysis, in which canonical Tcf/Lef binding sites have been identified (Riese et al. 1997; Eastman and Grosschedl 1999). Although vertebrate targets have included genes responsible for cell cycle progression (He et al. 1998; Tetsu and McCormick 1999) and dorsal-ventral axis specification (Brannon et al. 1997), none are directly associated with specifying a particular cell fate.

Our recent experiments have shown that Wnt signals are necessary and sufficient to promote the specification of neural crest as pigment cells (Dorsky et al. 1998). *Wnt-1* and *Wnt-3a* are expressed at the correct time and place to influence fate decisions made by premigratory neural crest cells. In the zebrafish, neural crest cells adjacent to domains of Wnt expression primarily produce pigment, whereas cells more distant from the Wnt signals primarily produce neurons and glia. By misexpressing mRNA in individual cells, we were able to demonstrate that β -catenin promotes pigment cell formation,

whereas dominant-negative forms of Tcf and Wnt inhibit the pigment fate. We were therefore interested in whether a Wnt target gene exists in neural crest cells, providing a direct link between extracellular signals and cell fate specification.

One possible mechanism by which pigment cell specification could take place is the direct control of genes necessary and sufficient for adopting the pigment cell fate. A candidate Wnt target gene that fulfills this role in zebrafish is *nacre*, which encodes a helix-loop-helix leucine zipper transcription factor homologous to MITF (microphthalmia-associated transcription factor) (Lister et al. 1999). *nacre* is expressed in differentiating neural crest-derived melanophores, as well as the retinal pigmented epithelium (Lister et al. 1999), and the product of its mammalian homolog *MITF* directly binds the promoters of pigment cell-specific genes such as *TRP-1* (Yasumoto et al. 1997; Bertolotto et al. 1998b). Misexpression of *nacre* or *MITF* can promote pigment cell phenotypes in nonpigment cells (Tachibana et al. 1996; Lister et al. 1999), demonstrating that it is a regulatory gene sufficient to specify pigment cell fate. Moreover, loss of *nacre* or *MITF* function results in a failure of neural crest-derived melanocytes to differentiate (Opdecamp et al. 1997; Lister et al. 1999), demonstrating that it is required for this cell fate. These properties led us to hypothesize that *nacre* may be directly regulated by Wnt signaling in the premigratory neural crest.

In this paper we show that an 838-bp *nacre* promoter/enhancer, which is sufficient to drive tissue-specific expression in vivo, contains three Tcf/Lef binding sites. These sites are necessary for specific interaction with zebrafish Lef1 in vitro and are necessary for regulation of the promoter/enhancer by Wnt signaling in a melanoma cell line. Finally, we show that the Tcf/Lef binding sites are necessary for proper expression in zebrafish embryos. Taken together, our results support a model in which the *nacre* gene is a direct target of Wnt signaling and establish a molecular pathway from extracellular signal to specification of cell fate.

Results

We observed that the human melanocyte-specific *MITF* promoter (Fuse et al. 1996) contains several putative Tcf/Lef binding sites, hallmarks of Wnt/ β -catenin-mediated transcriptional control (Riese et al. 1997; Eastman and Grosschedl 1999). To test the hypothesis that *nacre* is a target of the Wnt/ β -catenin pathway in zebrafish, we isolated a promoter/enhancer region for this gene from a genomic phage library. This genomic fragment contains the translation initiation site for *nacre* and an 836-bp upstream region with a potential transcription start site, a cAMP response element (CRE), and several consensus Tcf/Lef binding sites (Fig. 1A). These CRE and Tcf/Lef sites are not absolutely conserved between the human and zebrafish promoters in either their sequences or their positions from the transcription start site (data not

[Key Words: Wnt; β -catenin; *nacre*; neural crest; *MITF*]

⁴Requests for materials should be directed to rdorsky@u.washington.edu.

⁵Corresponding author.

E-MAIL rtmooon@u.washington.edu; FAX (206) 543-0858.

Figure 1. (A) Schematic diagram of the 836-bp *nacre* promoter/enhancer. Three Tcf/Lef binding sites, a cAMP response element (CRE), and the transcription start site are indicated. The sequences of the Tcf/Lef consensus and sites S1, S2, and S3 are listed, and the bases mutated to inactivate them are listed below. Arrows indicate an additional consensus base (C or G) that appears in these and all other published binding sites. The non-consensus base in site 3 is boxed. (B) Constructs used in this study are referenced in the text by the names indicated (left). To rescue function in the construct with three mutant Tcf/Lef sites, five replacement binding sites were inserted in *nacMS+Lef>nac* at the indicated position.

shown). To examine whether the putative *nacre* promoter/enhancer can direct proper spatial control of gene expression, we injected one-cell zebrafish embryos with the 836-bp DNA fragment driving a *green fluorescent protein* (GFP) reporter gene (*nac>GFP*, Fig. 1B). Mosaic gene expression is typical for transient transgenics in zebrafish, and because the neural crest is derived from very few precursor cells, reporter efficiency is decreased further. Despite these obstacles, we were able to analyze the fate of the few reporter-expressing cells in injected animals. In this transient expression assay, 18% of injected embryos showed GFP expression in one or more pigment cells (Fig. 2A,B); and strikingly, no expression was observed in other crest derivatives or outside the neural crest.

To determine whether control elements are sufficient for the correct initiation of gene expression, we used the promoter/enhancer to drive expression of wild-type *nacre* cDNA in *nacre*^{-/-} embryos, again by DNA injection at the one-cell stage. For cDNA expression to rescue the *nacre*^{-/-} phenotype, it must be expressed in premigratory neural crest cells, at the same time as the endogenous gene. In 34% of *nacre*^{-/-} embryos injected with the *nac>nac* construct (Fig. 1B), we observed rescue of melanophores, which are normally absent (Fig. 2C,D; Table 1). In addition, all of the melanin-containing cells that we observed had normal melanophore shape and

Figure 2. Analysis of *nacre* promoter/enhancer function in vivo. (A) (Arrow) A melanophore in a wild-type embryo injected at the one-cell stage with the *nac>GFP* construct; (B) the same cell is labeled with GFP; (C) 48-hr *nacre*^{-/-} embryo lacks melanophores (dorsal view); (D) a *nacre*^{-/-} embryo injected at the one-cell stage with the *nac>nac* construct contains melanophores (arrows).

were found in correct embryonic locations, in contrast to the pigment cells derived after *nacre* was misexpressed by mRNA injection or heat shock induction (Lister et al. 1999). We conclude that this 836-bp fragment contains both a functional promoter and all of the elements sufficient to drive normal *nacre* expression at the correct time and place to influence pigment cell formation.

If the *nacre* promoter/enhancer is directly controlled by Wnt/ β -catenin signaling, it should bind to Tcf/Lef proteins in vitro, consistent with known signaling mechanisms (Bienz 1998; Eastman and Grosschedl 1999). We initially identified two consensus binding sites (S1, S2; Fig. 1A) in the 836-bp fragment, based on existing Tcf/Lef binding sequences (Waterman et al. 1991; Brannon et al. 1997; Riese et al. 1997). In EMSAS, a fragment of the promoter/enhancer containing these sites bound recombinant zebrafish Lef1 protein (Dorsky et al. 1999; Fig. 3A, lane 1). However, mutation of both sites did not abolish Lef1 binding (Fig. 3B, lane 2), indicating that at least one cryptic binding site exists in this fragment. DNase I footprinting (not shown) identified an additional binding site in this region (S3; Fig. 1A), and an oligonucleotide containing this site competes for Lef1 binding of the entire fragment (Fig. 3A, lanes 2,3). In contrast, a version of this oligonucleotide with mutated Tcf/Lef binding nucleotides is unable to compete for Lef1 binding (Fig. 3A, lanes 4,5). Although S3 differs from the consensus Tcf/Lef binding sequence by a single base (box; Fig. 1A), it contains an additional conserved base identified previously in an optimal binding sequence (van de Wetering et al. 1997). We found that a C or G nucleotide at this position is present in all published Tcf/Lef sites and the three sites in the *nacre* promoter/enhancer (arrows; Fig. 1A). Mutation of all three Tcf/Lef

Table 1. Rescue of *nacre*^{-/-} embryos

Promoter construct	Embryos injected (n)	Embryos with melanophores (n)
<i>nac > nac</i>	123	42
<i>nacMS > nac</i>	165	0
<i>nacMS + Lef > nac</i>	107	31

Figure 3. Binding of Lef1 to the *nacre* promoter/enhancer. (A) The 836-bp fragment binds to in vitro-translated zebrafish Lef1 (Dorsky et al. 1999) (lane 1). Excess cold S3 probe is able to compete for Lef1 binding (lanes 2,3). In contrast, excess mutant S3 probe (see Fig. 1A for sequence) is unable to compete for Lef1 binding (lanes 4,5). (B) When S1 and S2 are mutated (MS 1,2), the promoter/enhancer still binds Lef1 (lanes 1,2). Mutation of all three sites (MS 1,2,3) eliminates Lef1 binding (lanes 3,4).

sites confirmed that they are necessary to promote binding to Lef1 protein in vitro (Fig. 3B, lane 4). We conclude that the *nacre* promoter/enhancer region contains three legitimate Tcf/Lef binding sites.

Before testing the importance of the Tcf/Lef sites in vivo, we first needed to confirm the prediction that β -catenin and Tcf/Lef could regulate these sites in a well-established cell culture assay. Either activation by β -catenin or inhibition by dominant-negative Tcf would establish that *nacre* was a target of the Wnt/ β -catenin pathway. Because the *nacre* promoter/enhancer, like the human *MITF* promoter (Fuse et al. 1996), acts in a tissue-specific fashion, we chose the mouse B16 melanoma cell line that had been used previously to study the regulation of *MITF* (Bertolotto et al. 1996). The 836-bp promoter/enhancer was inserted in front of the *luciferase* (*luc*) gene in the pGL3 reporter vector (*nac>luc*; Fig. 1B) and transfected into B16 cells. *nac>luc* showed high basal luciferase expression in these cells, which could not be increased by cotransfection with β -catenin (not shown). Because reporter activity was already very high in these cells, we tested its response to zebrafish Δtcf , similar to a *Xenopus* construct that blocks activation of Wnt/ β -catenin target genes (Molenaar et al. 1996). We used Tcf rather than Lef in this assay because Lef is unable to repress *siamois* transcription in *Xenopus* (Brannon et al. 1999). Cotransfection of Δtcf efficiently repressed the activity of *nac>luc* in B16 cells (Fig. 4). We then cotransfected *nac>luc* with full-length zebrafish *tcf3*, in the presence or absence of excess β -catenin. Although overexpression of full-length *tcf3* was able to repress activity of *nac>luc*, just as shown previously with the *Xenopus siamois* promoter (Brannon et al. 1997), addition of β -catenin was able to restore reporter activity to basal levels (Fig. 4). Strikingly, the repression of *nac>luc* by Δtcf was largely eliminated when all three Tcf/Lef sites were mutated in the construct *nacMS>luc*

(Fig. 1B), even though the basal activity was unaffected (Fig. 4). The high basal activity of *nacMS>luc* suggests that additional factors in B16 melanoma cells may be able to activate this construct in a Wnt-independent manner. Taken together, these data demonstrate that the Tcf/Lef binding sites are required for regulation of *nacre* expression by the Wnt pathway.

Based on these results we hypothesized that *nacre* is a direct target of the Wnt signaling pathway via β -catenin and Tcf/Lef-mediated transcription in vivo. To test this hypothesis, we used the mutant promoter/enhancer to drive *nacre* cDNA expression and attempted to rescue the *nacre*^{-/-} phenotype by DNA injections. As mentioned previously, the *nac>nac* construct is able to promote melanophore development in *nacre*^{-/-} embryos (Table 1). In contrast, mutation of the three Tcf/Lef binding sites (*nacMS>nac*; Fig. 1B) completely eliminated the ability of the promoter/enhancer to rescue the melanophore fate (Table 1). To assess whether replacing Tcf/Lef binding sites in the mutant construct was sufficient to restore normal expression, we reintroduced five synthetic sites into the mutant promoter/enhancer between S3 and the CRE (*nacMS+Lef>nac*; Fig. 1B). The replacement Tcf/Lef sites promoted melanophore formation in 29% of injected embryos (Table 1), indicating that the absolute positions of Tcf/Lef sites are not critical to their ability to rescue promoter function. These experiments show that transcriptional control of *nacre* expression via Tcf/Lef sites is necessary for the normal function of this gene in the developing embryo. Moreover, these data further support the hypothesis that Wnt signaling normally serves to activate *nacre* transcription in melanophore precursors.

Discussion

Our data indicate that Tcf/Lef sites in the *nacre* promoter/enhancer are directly modulated by Wnt and β -catenin. We found that β -catenin overexpression relieves repression by Tcf in B16 cells, consistent with

Figure 4. The *nacre* promoter/enhancer is regulated by the Wnt pathway. A wild-type promoter/enhancer-luciferase reporter construct (*nac>luc*; Fig. 1B) is repressed 6.8-fold by cotransfection with $\Delta tcf3$ in B16 melanoma cells. This reporter construct is also repressed by full-length *tcf3*, but this repression can be relieved by excess β -catenin. In contrast, a construct with all three Tcf/Lef sites mutated (*nacMS>luc*; Fig. 1B) is not significantly repressed by $\Delta tcf3$. Luciferase activity is represented in arbitrary units, mean of four experiments normalized to cotransfection with β -galactosidase. Error bars, S.E.M.

other Wnt-responsive genes (Bienz 1998; Eastman and Grosschedl 1999). By mutation of Tcf/Lef binding sites, it is possible to distinguish whether target gene expression is modulated by direct activation or by relief of repression. For example, mutation of the *siamois* promoter results in a derepression of reporter expression in the *Xenopus* embryo (Brannon et al. 1997). We propose that Tcf/Lef sites in the *nacre* promoter/enhancer are required for the activation of transcription, because mutations result in the loss of expression in vivo.

A seemingly contradictory result is the difference in reporter activity in B16 melanoma cells, where our mutant construct was highly active. These data could lead to the conclusion that Tcf/Lef sites are required for activation in one case and repression in the other. However, we believe that these experiments illustrate the fundamental differences between a committed melanocyte lineage and unspecified neural crest cells. Because B16 cells are derived from tissue that has become committed to produce melanocytes, they already express high levels of MITF (Bertolotto et al. 1996; Mahalingam et al. 1997). In contrast, unspecified neural crest cells in vivo are still multipotent and are not likely to express tissue-specific factors found in melanoma lines. It is therefore probable that initial activation of *nacre* transcription in the embryo requires Wnt/ β -catenin signaling as well as other factors, whereas this activation has already taken place in B16 cells. Furthermore, in both systems we can show that the *nacre* promoter/enhancer responds to Wnt signals in a manner dependent on Tcf/Lef binding sites.

Although Wnt signaling is present in many places during embryonic development, the *nacre* gene is activated specifically in melanophores and retinal pigmented epithelium, suggesting that other tissue-specific elements regulate its expression. Consistent with this idea, we found that the *nac>luc* construct is inactive in other, nonmelanocyte cell lines, even when cotransfected with β -catenin and/or Lef1 (not shown). Similar integration of signal and tissue specificity was observed with the human *MITF* promoter, through response to cAMP (Bertolotto et al. 1998a) and transactivation by PAX3 (Watanabe et al. 1998). Our data suggest that integration of multiple signals such as cAMP, pax3, and Wnt could serve to limit *nacre* expression to a subset of neural crest in zebrafish.

Taken with our previous work demonstrating that Wnt signaling is necessary and sufficient for the pigment cell fate (Dorsky et al. 1998), the present study extends our knowledge of cell fate specification by identifying a key regulatory gene that is directly activated by localized Wnt signals. The position of *nacre*/*MITF* at the top of a hierarchy of pigment cell specification genes (Tachibana et al. 1996) and the function of Nacre/MITF protein as a transcription factor (Yasumoto et al. 1994) allow a direct link to be drawn between cell-cell signaling and fate determination. Interestingly, although Wnt signaling promotes multiple pigment cell fates, including xanthophores (Dorsky et al. 1998), *nacre* function is not required for xanthophore development (Lister et al. 1999).

Additional target genes besides *nacre* may therefore be downstream of Wnt signaling, resulting in the promotion of other pigment cell types. As a general mechanism, the regulation of *nacre* by Wnt signaling may serve as a model demonstrating how environmental signals promote cell type diversity during development.

Materials and methods

Cloning of *nacre* promoter/enhancer

A probe comprising the first 271 nucleotides of the *nacre* cDNA was used to screen a zebrafish genomic phage library (Stratagene) using standard methods. Positive clones were purified and characterized by Southern blot analysis. A 2.1-kb fragment was subcloned and sequenced and found to contain the 5' end of the *nacre* cDNA. A 836-bp fragment including the first 10 amino acids of *nacre* was fused to GFP, and fragments ending in the *nacre* 5'-untranslated region were fused to luciferase (pGL3, Promega) and *nacre* cDNAs. The sequence for the *nacre* promoter/enhancer has been submitted to GenBank under accession no. AF211890.

DNA microinjections and EMSAs

Embryos were obtained from wild-type lines and a viable stock homozygous for a null mutation in *nacre* (Lister et al. 1999). DNA constructs were diluted to 100 ng/ μ l and were injected into one-cell zebrafish embryos using standard methods. Approximately 0.25–1 nl of DNA was injected into each embryo.

DNA probes were gel purified and end-labeled by standard procedures using Klenow DNA polymerase. Zebrafish Lef1 protein (Dorsky et al. 1999) was produced using the TNT SP6 reticulocyte lysate kit (Promega). Mobility shift assays and competition analyses were performed as described previously (Brannon et al. 1997).

Mutagenesis and Tcf/Lef site replacement

nacre promoter/enhancer constructs were mutated using the GeneEditor mutagenesis kit (Promega). Mutagenic oligonucleotides were 28–32 bases in length and contained the mismatched bases shown in Figure 1. All mutations introduced new restriction sites. Tcf/Lef site replacement oligonucleotides were designed using the sequence of TOPflash (van de Wetering et al. 1997) and included ends compatible with a unique *SpeI* site in the *nacre* promoter/enhancer. Oligonucleotides were annealed, kinased, and ligated into a mutant construct digested with *SpeI* and dephosphorylated. This ligation destroyed the *SpeI* site and created a new *DraIII* site. All clones were confirmed by sequencing.

B16 cell transfections and luciferase assays

B16 cells (gift from Dr. Vincent Hearing, NCI, Bethesda, MD) were grown in DMEM + 10% FBS. Cells were plated to a density of 1×10^5 /well and transfected with Lipofectamine Plus (GIBCO) following the manufacturer's instructions. After 24 hr, cells were lysed and assayed for luciferase activity with a Berthold Luminometer. β -Galactosidase activity was measured using Galactolite (Tropix).

Acknowledgments

We thank Vincent Hearing for providing B16 cells, James Lister for providing the *nacre* cDNA and embryos, Marian Waterman for providing Lef1 protein and antibodies, Jeffrey Miller for assistance with Western blots, members of the Nathanson and McKnight laboratories for assistance with luciferase assays, and Julie Kiefer and David Kimelman for comments on the manuscript. R.I.D. acknowledges support as an Associate, and R.T.M. as an Investigator of the HHMI. This research was funded by the HHMI (R.I.D. and R.T.M.) and the NIH (D.W.R.).

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Bertolotto, C., K. Bille, J.P. Ortonne, and R. Ballotti. 1996. Regulation of tyrosinase gene expression by cAMP in B16 melanoma cells involves

- two CATGTG motifs surrounding the TATA box: Implication of the microphthalmia gene product. *J. Cell Biol.* **134**: 747–755.
- Bertolotto, C., P. Abbe, T.J. Hemesath, K. Bille, D.E. Fisher, J.P. Ortonne, and R. Ballotti. 1998a. *Microphthalmia* gene product as a signal transducer in cAMP-induced differentiation of melanocytes. *J. Cell Biol.* **142**: 827–835.
- Bertolotto, C., R. Busca, P. Abbe, K. Bille, E. Aberdam, J.P. Ortonne, and R. Ballotti. 1998b. Different cis-acting elements are involved in the regulation of *TRP1* and *TRP2* promoter activities by cyclic AMP: Pivotal role of M boxes (GTCATGTGCT) and of microphthalmia. *Mol. Cell. Biol.* **18**: 694–702.
- Bienzi, M. 1998. TCF: Transcriptional activator or repressor? *Curr. Opin. Cell Biol.* **10**: 366–372.
- Brannon, M., M. Gomperts, L. Sumoy, R.T. Moon, and D. Kimelman. 1997. A β -catenin/XTcf-3 complex binds to the *siamois* promoter to regulate dorsal axis specification in *Xenopus*. *Genes & Dev.* **11**: 2359–2370.
- Brannon, M., J.D. Brown, R. Bates, D. Kimelman, and R.T. Moon. 1999. XCBP is a XTcf-3 co-repressor with roles throughout *Xenopus* development. *Development* **126**: 3159–3170.
- Cadigan, K.M. and R. Nusse. 1997. Wnt signaling: A common theme in animal development. *Genes & Dev.* **11**: 3286–3305.
- Dorsky, R.I., R.T. Moon, and D.W. Raible. 1998. Control of neural crest cell fate by the Wnt signalling pathway. *Nature* **396**: 370–373.
- Dorsky, R.I., A. Snyder, C.J. Cretekos, D.J. Grunwald, R. Geisler, P. Haffter, R.T. Moon, and D.W. Raible. 1999. Maternal and embryonic expression of zebrafish *Lef1*. *Mech. Dev.* **86**: 147–150.
- Eastman, Q. and R. Grosschedl. 1999. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. *Curr. Opin. Cell Biol.* **11**: 233–240.
- Fuse, N., K. Yasumoto, H. Suzuki, K. Takahashi, and S. Shibahara. 1996. Identification of a melanocyte-type promoter of the *microphthalmia-associated transcription factor* gene. *Biochem. Biophys. Res. Commun.* **219**: 702–707.
- He, T.C., A.B. Sparks, C. Rago, H. Hermeking, L. Zawel, L.T. da Costa, P.J. Morin, B. Vogelstein, and K.W. Kinzler. 1998. Identification of c-MYC as a target of the APC pathway. *Science* **281**: 1509–1512.
- Lister, J.A., C.P. Robertson, T. Lepage, S.L. Johnson, and D.W. Raible. 1999. *nacre* encodes a zebrafish microphthalmia-related protein that regulates neural-crest-derived pigment cell fate. *Development* **126**: 3757–3767.
- Mahalingam, H., A. Watanabe, M. Tachibana, and R.M. Niles. 1997. Characterization of density-dependent regulation of the tyrosinase gene promoter: role of protein kinase C. *Exp. Cell Res.* **237**: 83–92.
- Molenaar, M., M. van de Wetering, M. Oosterwegel, J. Peterson-Maduro, S. Godsave, V. Korinek, J. Roose, O. Destree, and H. Clevers. 1996. XTcf-3 transcription factor mediates β -catenin-induced axis formation in *Xenopus* embryos. *Cell* **86**: 391–399.
- Opdecamp, K., A. Nakayama, M.T. Nguyen, C.A. Hodgkinson, W.J. Pavan, and H. Arnheiter. 1997. Melanocyte development in vivo and in neural crest cell cultures: crucial dependence on the Mitf basic-helix-loop-helix-zipper transcription factor. *Development* **124**: 2377–2386.
- Riese, J., X. Yu, A. Munsterlyn, S. Eresh, S.C. Hsu, R. Grosschedl, and M. Bienzi. 1997. LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic. *Cell* **88**: 777–787.
- Tachibana, M., K. Takeda, Y. Nobukuni, K. Urabe, J.E. Long, K.A. Meyers, S.A. Aaronson, and T. Miki. 1996. Ectopic expression of *MITF*, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics. *Nat. Genet.* **14**: 50–54.
- Tetsu, O. and F. McCormick. 1999. β -catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature* **398**: 422–426.
- van de Wetering, M., R. Cavallo, D. Dooijes, M. van Beest, J. van Es, J. Loureiro, A. Ypma, D. Hursh, T. Jones, A. Bejsovec et al. 1997. Armadillo coactivates transcription driven by the product of the *Drosophila* segment polarity gene *dTCF*. *Cell* **88**: 789–799.
- Watanabe, A., K. Takeda, B. Ploplis, and M. Tachibana. 1998. Epistatic relationship between Waardenburg syndrome genes *MITF* and *PAX3*. *Nat. Genet.* **18**: 283–286.
- Waterman, M.L., W.H. Fischer, and K.A. Jones. 1991. A thymus-specific member of the HMG protein family regulates the human T cell receptor C α enhancer. *Genes & Dev.* **5**: 656–669.
- Yasumoto, K., K. Yokoyama, K. Shibata, Y. Tomita, and S. Shibahara. 1994. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human *tyrosinase* gene. *Mol. Cell Biol.* **14**: 8058–8070.
- Yasumoto, K., K. Yokoyama, K. Takahashi, Y. Tomita, and S. Shibahara. 1997. Functional analysis of microphthalmia-associated transcription factor in pigment cell-specific transcription of the human tyrosinase family genes. *J. Biol. Chem.* **272**: 503–509.

Direct regulation of *nacre*, a zebrafish *MITF* homolog required for pigment cell formation, by the Wnt pathway

Richard I. Dorsky, David W. Raible and Randall T. Moon

Genes Dev. 2000, **14**:

Access the most recent version at doi:[10.1101/gad.14.2.158](https://doi.org/10.1101/gad.14.2.158)

References

This article cites 24 articles, 12 of which can be accessed free at:
<http://genesdev.cshlp.org/content/14/2/158.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).